Skip to main content

Advertisement

SpringerLink
Log in

IL-17 mediates resistance to anti-VEGF therapy

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy (pages 1114–1123).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Stroma-mediated development of anti-VEGF resistance.

Marina Corral Spence

References

  1. Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).

    Article  CAS  Google Scholar 

  2. Ferrara, N. & Kerbel, R.S. Nature 438, 967–974 (2005).

    Article  CAS  Google Scholar 

  3. Kieran, M.W., Kalluri, R. & Cho, Y.J. Cold Spring Harb. Perspect. Med. 2, a006593 (2012).

    Article  Google Scholar 

  4. Leek, R.D., Harris, A.L. & Lewis, C.E. J. Leukoc. Biol. 56, 423–435 (1994).

    Article  CAS  Google Scholar 

  5. Holash, J. et al. Science 284, 1994–1998 (1999).

    Article  CAS  Google Scholar 

  6. Chung, A.S. et al. Nat. Med. 19, 1114–1123 (2013).

    Article  CAS  Google Scholar 

  7. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. Nat. Rev. Drug Discov. 12, 217–228 (2013).

    Article  CAS  Google Scholar 

  8. De Palma, M. & Lewis, C. Cancer Cell 23 Issue 3, 277–286 (2013).

    Article  CAS  Google Scholar 

  9. Du, R. et al. Cancer Cell 13, 206–220 (2008).

    Article  CAS  Google Scholar 

  10. Bergers, G. & Song, S. Neuro Oncol. 7, 452–464 (2005).

    Article  CAS  Google Scholar 

  11. De Palma, M. et al. Cancer Cell 8, 211–226 (2005).

    Article  CAS  Google Scholar 

  12. Gabrilovich, D.I., Ostrand-Rosenberg, S. & Bronte, V. Nat. Rev. Immunol. 12, 253–268 (2012).

    Article  CAS  Google Scholar 

  13. Crawford, Y. et al. Cancer Cell 15, 21–34 (2009).

    Article  CAS  Google Scholar 

  14. Shojaei, F. et al. Nat. Biotechnol. 25, 911–920 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eleni Maniati and Thorsten Hagemann are at the Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.,

    Eleni Maniati & Thorsten Hagemann

Authors
  1. Eleni Maniati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Hagemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Hagemann.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maniati, E., Hagemann, T. IL-17 mediates resistance to anti-VEGF therapy. Nat Med 19, 1092–1094 (2013). https://doi.org/10.1038/nm.3333

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3333

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation